Country
United Kingdom
GW Pharmaceuticals Plc has raised $300 million in a secondary offering on the US Nasdaq, providing it with capital to commercialise its recently approved cannabinoid medicine Epidiolex for the treatment of seizures associated with t
Full text available to subscribers only. Click here for information on subscribing to MedNous.